HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Igdrasol Inc.

Division of Sorrento Therapeutics Inc.

Latest From Igdrasol Inc.

Sorrento Adds ADC Development Capabilities With Concortis Buyout

The San Diego biotech hopes to develop antibody-drug conjugate therapies for cancer that will offer more specific targeting and more stable drug-to-antibody ratios, compared to ADCs now on the market. The acquisition is just the latest in a busy stretch of deal-making for Sorrento.

BioPharmaceutical United States

Deals Shaping The Medical Industry, June 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • IgDraSol Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sorrento Therapeutics Inc.
  • Senior Management
  • Vuong Trieu, PhD, CEO
    Larn Hwang, PhD, COO
    Kouros Motamed, PhD, CSO
  • Contact Info
  • Igdrasol Inc.
    Phone: (714) 445-0127
    11100 Warner Ave.
    Ste. 266
    Fountain Valley, CA 92708